Added to YB: 2026-03-16
Pitch date: 2026-03-12
NVO [neutral]
Novo Nordisk A/S
+0.02%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 247.00
Price Target
N/A
Dividend
4.68%
EV/EBITDA
7.83
P/E
10.85
EV/Sales
3.93
Sector
Pharmaceuticals
Category
value
Show full summary:
Theodosian Capital | Stocks Update 12/3/2026 - NOVOB – If you can’t beat them…
NOVOB (update): Struck deal w/ Hims & Hers to distribute Ozempic/Wegovy at self-pay prices; Hims stops advertising compounded GLP-1s, ending patent dispute. Trades 11.7x 2027 EPS w/ 4.7% yield vs Eli Lilly at 23.1x—looks cheap but author notes long-held view.
Read full article (1 min)